|
Median age at SCT (range)
|
53.6 years old (18–69)
|
|
Median follow-up (range)
|
21 months (3.3–146)
|
|
Interval between diagnosis and CR1 (range)
|
56.5 days (18–170)
|
|
Intervals from CR1 to SCT (range)
|
81.5 days (11–286)
|
|
Median year of SCT
|
2009 (2000–2013)
|
|
Secondary AML, N (%)
|
19 (15.2%)
|
|
CMV+ patient, N (%)
|
84 (68.3%)
|
|
CMV+ donor, N (%)
|
65 (68.3%)
|
|
Karnofsky >90% at SCT, N (%)
|
83 (70.3%)
|
|
Gender, N (%)
|
|
Male
|
71 (57%)
|
|
Female
|
54 (43%)
|
|
Donor type, N (%)
|
|
Sibling
|
60 (48%)
|
|
Unrelated
|
54 (43.2%)
|
|
Cord blood
|
10 (8%)
|
|
Source of SC, N (%)
|
|
BM
|
19 (15.2%)
|
|
PB
|
95 (76%)
|
|
CB
|
10 (8%)
|
|
Conditioning regimen, N (%)
|
|
MAC
|
51 (41%)
|
|
RIC
|
73 (59%)
|
|
In vivo T cell depletion, N (%)
|
64 (51%)
|
|
ATG
|
47 (38%)
|
|
Alemtuzumab
|
17 (14%)
|
|
Monosomal karyotype, N (%)
|
86 (82.7%)
|
|
Missing, N
|
21
|
|
Complex karyotype, N (%)
|
98 (90.7%)
|
|
Missing, N
|
17
|
|
Inv(3), N (%)
|
3 (2.9%)
|
|
Missing, N
|
20
|
|
-7, N (%)
|
41 (39%)
|
|
Missing, N
|
20
|
|
-5/5q-, N (%)
|
58 (55.2%)
|
|
Missing, N
|
20
|
|
Both -7 and -5/5q-, N (%)
|
28 (26.9%)
|
